Arrowhead Pharmaceuticals · 2 months ago
Scientist/Senior Scientist, Molecular Biology
Arrowhead Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative drugs for diseases with a genetic basis. The role of Senior Scientist in Molecular Biology involves leading antibody discovery efforts to support platform development and drug delivery initiatives.
BiotechnologyHealth CareNanotechnologyPharmaceutical
Responsibilities
Design, construct, and screen phage display libraries to identify lead antibodies
Perform molecular cloning, antibody gene assembly, and expression vector design
Express and purify recombinant antibodies using bacterial and mammalian expression systems
Characterize lead antibodies using binding assays (ELISA, SPR, BLI) and functional assays
Collaborate with cross-functional project teams to advance lead antibodies through drug development stages
Maintain accurate documentation and present findings at internal meetings
Qualification
Required
Ph.D. in Biology, Biochemistry, Molecular Biology, or a related field
Hands-on experience with phage display technology for antibody discovery
Proficiency in molecular cloning, PCR, and gel electrophoresis
Experience with antibody expression and purification using E. coli, HEK293, and CHO systems
Strong analytical and problem-solving skills, with the ability to troubleshoot experiments independently
Excellent record-keeping, communication, and collaboration skills
Proven ability to adapt to fast pace and evolving research priorities
Track record of scientific productivity, including peer-reviewed publications, conference presentations, or patents
Preferred
Industry or postdoc experience
Benefits
Competitive salaries
Excellent benefit package
Company
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Funding
Current Stage
Public CompanyTotal Funding
$2.45BKey Investors
Sarepta TherapeuticsSixth StreetSilence Therapeutics
2026-01-07Post Ipo Equity· $200M
2026-01-07Post Ipo Debt· $625M
2024-11-26Post Ipo Equity· $325M
Leadership Team
Christopher Anzalone
President and Chief Executive Officer
Recent News
2026-01-14
2026-01-08
Company data provided by crunchbase